Skip to main content

The independent medical news service

Prostate cancer

18-04-2019 | Diabetes | News | Article

Study bolsters evidence for 5 alpha-reductase inhibitor link to type 2 diabetes

Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.

18-04-2019 | Oncology | News | Article

68Ga-PSMA-11 PET shows ‘high accuracy’ for localizing recurrent prostate cancer

Positron emission tomography using 68gallium-labeled ligands of the prostate-specific membrane antigen is accurate, reproducible, and safe in localizing biochemically recurrent prostate cancer, according to the results of a prospective trial.

11-04-2019 | Oncology | News | Article

Prostate cancer incidence, mortality has decreased or stabilized in many countries

Research reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, shows that the incidence of prostate cancer and associated mortality has generally declined or remained steady in most of the countries with available data.

08-04-2019 | Oncology | News | Article

SPARTAN: Apalutamide benefit seen for luminal, basal nonmetastatic CRPC

Supplementing androgen deprivation therapy with apalutamide improves metastasis-free survival in patients with the luminal and basal subtypes of nonmetastatic castration-resistant prostate cancer, indicates an analysis of the randomized SPARTAN trial.

08-04-2019 | Oncology | News | Article

FDA approves point-of-care PSA test

Click through to read the details

31-03-2019 | Oncology | News | Article

Abiraterone may raise mortality risk in men with prostate cancer, CVD

Among men initiating abiraterone acetate for advanced prostate cancer, the mortality risk may be higher for those with versus without pre-existing cardiovascular disease, suggests a real-world study presented at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA.

27-03-2019 | Prostate cancer | News | Article

Carbon ion radiotherapy may reduce future tumor risk after prostate cancer

Patients who receive carbon ion radiotherapy for localized prostate cancer have a significantly lower risk for subsequent primary cancers than those treated with photon radiotherapy or surgery, retrospective study data suggest.

21-03-2019 | Oncology | News | Article

Docetaxel add-on improves outcomes in high-risk localized prostate cancer

Adding docetaxel chemotherapy to standard long-term androgen suppression plus radiotherapy significantly improves survival in patients with high-risk nonmetastatic prostate cancer, show data from the NRG Oncology RTOG 0521 study.

19-03-2019 | Oncology | News | Article

AR-V7 status predicts abiraterone, enzalutamide response in mCRPC

Men positive for androgen receptor splice variant 7 in circulating tumor cells derive little benefit from abiraterone or enzalutamide in the treatment of metastatic castration-resistant prostate cancer, US researchers report.

14-03-2019 | Oncology | News | Article

Aspirin does not improve prostate cancer-specific survival, but may reduce lung cancer incidence

A Danish study has found no protective effect of low-dose aspirin taken after diagnosis on prostate cancer-specific mortality, while South Korean research has identified a link between long-term use of the nonsteroidal anti-inflammatory drug and a reduced risk for incident lung cancer.

13-03-2019 | Prostate cancer | News | Article

Phase III data show no support for PROSTVAC in mCRPC

A phase III trial investigating the efficacy of PROSTVAC, a viral vector–based immunotherapy, in the treatment of metastatic castration-resistant prostate cancer was stopped early due to a lack of positive results, say researchers.

12-03-2019 | Prostate cancer | News | Article

Intense neoadjuvant ADT explored in locally advanced prostate cancer

Intense androgen deprivation therapy before radical prostatectomy benefits some patients with locally advanced prostate cancer, report researchers who found that results may be better with a four-drug than a two-drug regimen.

08-03-2019 | Prostate cancer | News | Article

Hypofractionated RT noninferior to conventional for QoL in low-risk prostate cancer

Hypofractionated radiotherapy is similar to conventional radiotherapy when it comes to health-related quality of life in men with low-risk prostate cancer, according to the RTOG 0415 phase III randomized controlled trial.

06-03-2019 | Prostate cancer | News | Article

Enzalutamide preserves QoL in men with nonmetastatic CRPC

Men with nonmetastatic, castration-resistant prostate cancer receiving enzalutamide maintain their low baseline pain levels and prostate cancer symptom burden and report high health-related quality of life, indicates a patient-reported outcomes analysis of the phase III PROSPER study.

25-02-2019 | Prostate cancer | News | Article

Combined radium-223, abiraterone acetate not endorsed for CRPC

Combining radium-223 with abiraterone acetate plus prednisone or prednisolone is not recommended for patients with castration-resistant prostate cancer and bone metastases, ERA 223 researchers report.

22-02-2019 | Prostate cancer | News | Article

CheckMate 650: Nivolumab–ipilimumab potential for mCRPC demonstrated

The combination of nivolumab and ipilimumab has antitumor activity in men with metastatic castration-resistant prostate cancer, suggest CheckMate 650 data.

19-02-2019 | Prostate cancer | News | Article

ARCHES shows enzalutamide benefit for mCSPC

Supplementing androgen deprivation therapy with enzalutamide delays radiologic progression in men with metastatic castration-sensitive prostate cancer, indicate phase III trial findings presented at the 2019 ASCO Genitourinary Cancers Symposium.

18-02-2019 | Prostate cancer | News | Article

Darolutamide reduces CRPC metastasis risk

Addition of the androgen receptor antagonist darolutamide to androgen deprivation therapy improves metastasis-free survival in patients with castration-resistant prostate cancer, indicate ARAMIS trial results.

15-02-2019 | Prostate cancer | News | Article

Further support for [177Lu]-PSMA-617 in men with mCRPC

Results from an expansion cohort add support for the use of lutetium-177-prostate-specific membrane antigen-617 in heavily pretreated men with metastatic castration-resistant prostate cancer.

15-02-2019 | Prostate cancer | News | Article

Real-world data confirm better mCRPC OS with hormonal therapy in Black versus White men

An analysis of a US database shows that Black individuals who receive abiraterone acetate or enzalutamide for metastatic castration-resistant prostate cancer have better overall survival than their White counterparts.

image credits